The company highlighted several key achievements during the fourth quarter, including the successful completion of 13 cases with the vCLAS™ System under FDA Expanded Access authorization. Additionally, Adagio announced the peer-reviewed publication of results from its U.S. Early Feasibility Study evaluating its ultralow temperature cardiac ablation technology, which demonstrated a favorable safety profile.
Adagio also strengthened its leadership team by appointing Sean Salmon to its Board of Directors and enhancing its executive leadership with the addition of Marie-Claude Jacques and Antwan Gipson in senior roles. The company has been actively engaging with investors and attending industry conferences to bolster its market presence.
Looking ahead, Adagio is focused on advancing its ULTA technology towards commercialization and preparing for the potential approval of its vCLAS™ System for the treatment of ventricular tachycardia. The company has completed enrollment in its pivotal FULCRUM-VT trial, which is expected to support its premarket approval application. With cash and cash equivalents of $17.1 million as of December 31, 2025, Adagio is well-positioned to fund its ongoing development activities and FDA submission efforts.
